Novartis is buying its way into the next wave of genetic medicine — Avidity could be the entry point

Swiss pharmaceutical giant Novartis AG (NVS) is reportedly on the verge of acquiring U.S. biotech firm Avidity Biosciences Inc. (RNA) for a price in excess of US$70 per share, according to people familiar with the matter. The deal — if finalised — would mark a bold step in Novartis’s broader push to replenish its pipeline amid major patent expirations and intensifying competitive pressure.

Why is Novartis pursuing Avidity Biosciences?

Novartis’s interest in Avidity stems from a convergence of strategic pressures and opportunities. On the pressure side, Novartis is facing looming generics and biosimilars challenges across several of its blockbuster franchises, including Entresto, Cosentyx and Xolair. In response, it has adopted a strategy of acquiring innovative biotech platforms and specialty assets rather than relying solely on internal drug development. Acquiring Avidity would fit squarely into the model of using high-growth, next-generation modalities to drive future growth.

Avidity Biosciences specialises in antibody-oligonucleotide conjugate (AOC) technology targeting neuromuscular disorders such as Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1). Its AOC platform allows targeted delivery of RNA therapeutics to muscle tissue, a frontier that fits with the broader rare-disease, precision-medicine trend. The move reflects how Novartis is aligning with the industry shift toward rare disease and RNA-based therapies.

By acquiring Avidity, Novartis would gain access to a pipeline of three clinical-stage programmes in rare neuromuscular indications along with a scalable platform that could potentially be applied beyond muscle disease into cardiology or immunology. For a large pharma under pressure to deliver innovations, such a deal could be transformational.

What does Avidity bring to the table?

Based in San Diego, USA, Avidity Biosciences is a relatively young biotech entity focused entirely on its AOC platform. The company’s lead candidate, delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy with exon 44 skipping, has been cited by analysts as a potential multi-billion-dollar opportunity. In parallel, Avidity’s early-stage work in FSHD and DM1 further broadens its potential value. Early investor and analyst commentary note that the AOC platform might overcome some of the delivery challenges that have historically limited RNA therapeutics outside liver-targeted indications.

The combination of Avidity’s tech novelty, promising pipeline and alignment with rare neuromuscular disease makes it a compelling target for a pharma company seeking high-margin, growth-oriented assets. Institutional analysts have labelled the company’s profile as “platform-plus-pipeline”, adding strategic upside if successfully commercialised.

How steep is the deal premium — and what does that suggest?

The reported acquisition price of more than US$70 per share implies a significant premium relative to Avidity’s trading levels in recent months. While the exact structure remains unconfirmed, some media outlets estimate a premium of at least ~40 %. For example, one Swedish-language source reported a purchase price over $70 with a ~42 % premium compared with a closing share price of ~$49.15. The implied market capitalisation of Avidity — assuming ~6.8 billion USD at ~$70/share — highlights the scale of investment that Novartis is prepared to deploy.

Such a premium signals Novartis’s confidence in the strategic value of the acquisition, but it also raises the bar for execution. Paying a high valuation implies that Avidity must deliver on its science, regulatory approvals and commercialisation — or face potential investor backlash. For Novartis shareholders, the key question will be whether the acquisition delivers value relative to opportunity cost and integration risk.

What’s the market reaction and investor sentiment?

From a stock-market and sentiment perspective, the reported deal interest triggered a notable rally in Avidity’s shares. Following earlier reports that Novartis was evaluating a bid, Avidity’s stock surged 20-30 %. One estimate puts a 26 % jump after a Financial Times report. Institutional investor commentary reflected cautious optimism: analysts at Bank of America maintained a “Buy” rating, citing the biotech’s promising pipeline and takeover interest. However, other metrics flagged caution: for example Avidity carried a Zacks Rank of #4 (“Sell”) in one assessment due to the inherent risk of early-stage biotech.

For Novartis, the reaction is more muted but positive. While large pharma stocks often respond to major acquisitions with mixed sentiment (given risks of dilution, integration and regulatory scrutiny), investors appear supportive of the pipeline refresh initiative. Early institutional flows appear favourable, though detailed breakdowns of foreign-institutional or domestic holdings were not publicly disclosed at this time.

In short, the acquisition speculation has raised valuations, heightened investor expectations and increased scrutiny of execution risk. Stakeholders will watch closely for deal details, regulatory filings and subsequent developments.

How does this move fit broader industry and strategic trends?

This potential deal is symptomatic of three inter-locking trends in the pharmaceutical and biotech sectors. First, the rise of rare-disease and speciality-modalities M&A. Drug developers are shifting focus from large-volume, low-margin medicines toward high-impact, high-margin treatments for small patient populations, often with premium pricing. Second, the growing importance of RNA-based therapeutics and delivery technologies that extend RNA’s reach beyond the liver and into muscle, heart or central nervous system tissues. Avidity’s AOC platform embodies this shift. Third, Big Pharma’s increased acquisition of biotech companies as a strategic response to patent expirations (the “patent cliff”) and competitive pressure, especially in developed markets.

Novartis’s reported interest in Avidity aligns with its previous deal activity this year, including the acquisitions of Anthos Therapeutics and Regulus Therapeutics, as the company re-tools its innovation engine. If the Avidity deal closes, it would reaffirm Novartis’s intent to be a leader in rare disease and RNA-therapeutics, and might prompt competitive responses from other major pharma companies seeking to catch up. The broader implication: valuations for RNA/rare-disease platforms could continue to climb, raising the competitive stakes and deal multiples across the sector.

What are the key risks and watch-points for investors and stakeholders?

Despite the excitement, multiple caveats apply. First, the acquisition is still unconfirmed and talks could falter. Early reports emphasise that discussions are at a preliminary stage and no guarantee of closure. Second, Avidity’s lead programmes remain early to mid-stage — clinical and regulatory risk remains high. Even with Breakthrough Therapy designation in one case, successful commercialisation is far from certain. Third, integration risk looms for Novartis. Combining a nimble biotech culture with a large pharma organisation often presents challenges: cultural alignment, management complexity, cost-synergy realisation and regulatory compliance all need careful handling. Fourth, valuation risk: paying a high multiple implies high expectations, and any slippage in milestones or approvals could trigger investor disappointment. Finally, external risks such as pricing-policy changes, regulatory scrutiny, antitrust concerns or global macro disruption may affect the strategic outcome.

What could happen next and why does it matter for the future?

From a next-step standpoint, stakeholders should monitor four key developments. One, official announcement details: timing, price, structure (cash vs. stock), contingent milestones and regulatory conditions. Two, regulatory and antitrust scrutiny: large pharma biotech deals increasingly face investigation in multiple jurisdictions; oversight may delay closing or add conditions. Three, pipeline data readouts from Avidity’s clinical programmes — particularly del-zota for DMD — which will shape value realisation. Four, integration planning from Novartis: how success will be measured, synergies captured and commercial rollout executed.

Looking farther ahead, if the acquisition finalises at the reported level, it could set a new benchmark for RNA-therapeutics and rare-disease biotech valuations. Other major pharmaceutical companies may feel pressure to respond, potentially driving an uptick in deal volume and multiples in 2026. For Novartis, success in this acquisition could reinforce its transition toward rare-disease leadership and next-gen therapeutics, thereby helping to offset its patent cliff challenge.

What should shareholders and analysts focus on as the Novartis–Avidity deal progresses?

• Novartis AG is reportedly nearing an acquisition of Avidity Biosciences Inc. at a price exceeding US$70 per share, representing a substantial premium.

• The deal aligns with Novartis’s strategic pivot toward rare-disease and RNA-based therapies as a response to looming patent expirations.

• Avidity Biosciences offers a novel antibody-oligonucleotide conjugate platform and is advancing a pipeline focused on DMD, FSHD and DM1.

• Stock-market reaction to the acquisition speculation has been strongly positive for Avidity, with shares rising 20-30 % amid takeover interest; institutional sentiment favours the biotech.

• Key risks include the early stage of the acquisition talks, pipeline uncertainty, valuation premium and integration complexities for Novartis.

• The outcome will have broader implications: a successful deal could raise valuations across the RNA/rare-disease sector and trigger further consolidation in Big Pharma.